enVVeno: 72% of VenoValve patients show clinically meaningful benefit; FDA filing on track for Q4 2024

enVVeno Medical Corp

72% of SAVVE trial patients achieved ≥3-point rVCSS improvement at a weighted average of 11 months post-surgery.
Overall average rVCSS improvement of 8.46 points for meaningful-benefit cohort; 9.29 points at two-year milestone.
94% of patients showed clinical improvement (≥1 point rVCSS) at a weighted average of 11 months post-implant.
Company expects to complete one-year data collection by September 2024 and file PMA for FDA approval in Q4 2024.
Cash and investments of $46.4M at Dec 31, 2023 expected to fund operations through FDA decision and end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.